The new Luxeon T is intended by Lumileds to be the primary LED sold into high-power, directional SSL products such as downlights and MR16 and PAR retrofit lamps. Philips Lumileds has introduced the new Luxeon T series of high-power LEDs ...
Tags: Philips, LEDs, green LED, solid-state lighting, SSL
Genzyme, a Sanofi company, has submitted a new drug application to the FDA seeking approval for KYNAMRO for the treatment of patients with homozygous familial hypercholesterolemia (HoFH). The submission is based on trial in which ...
Tags: KYNAMRO, homozygous familial hypercholesterolemia, HoFH
The European Commission (EC) has granted orphan drug designation to Sunesis Pharmaceuticals' Vosaroxin drug. Vosaroxin is a first-in-class anti-cancer quinolone derivative, (AQD), used for the treatment of acute myeloid leukemia (AML). ...
Tags: vosaroxin, AQD, AML, anti-cancer quinolone derivative
Furiex Pharmaceuticals said Takeda Global Research & Development Center has resubmitted New Drug Applications (NDAs) to the US Food and Drug Administration (FDA) for alogliptin and fixed-dose combination therapy alogliptin and pioglitazone ...
Tags: Furiex Pharmaceuticals, NDAs, alogliptin and pioglitazone
Boston-based Liberty Mutual Insurance is likely to unveil a mobile application to help employees easily manage numerous benefits using smart phones. As part of the MyLibertyMobile application, the firm has extended the functionality to ...
Tags: Liberty Mutual Insurance, mobile application, benefit management
Pfizer is considering buying NextWave Pharmaceuticals, a company that develops a liquid attention deficit hyperactivity disorder drug. In the second quarter of 2012, Pfizer signed an option and merger agreement with NextWave and made a ...
Tags: Pfizer, NextWave Pharmaceuticals, deficit hyperactivity disorder drug
Japanese carmaker Nissan has recorded 4.845 million units in global sales in the fiscal year 2011, up 15.8% from last year's 4.185 million units, as demand for its vehicles outperformed the total auto industry which increased 4.2%. Nissan ...
Tags: nissan, operating profits, record sales, vehicles, electric vehicle
AmDerma Pharmaceuticals and Oculus Innovative Sciences have signed a multi-country agreement to develop and commercialize Microcyn technology drug compounds for major dermatological conditions. The agreement includes licensing of the ...
Tags: Microcyn technology drug compounds, dermatology compounds
AstraZeneca and Ardelyx have signed a worldwide exclusive licensing agreement for Ardelyx's NHE3 inhibitor programme for the treatment of complications associated with end-stage renal disease (ESRD) and chronic kidney disease (CKD). The ...
Tags: RDX5791, Ardelyx, AstraZeneca, NHE3 inhibitor programme, NHE3
AtheroNova has entered into an agreement with Frontage Laboratories to commence work on the formulation, compounding and tabletization of the AHRO-001 tablets. Frontage will commence work on the analysis, formulation and validation of the ...
Tags: AtheroNova, AHRO-001, atherosclerosis
Alnylam Pharmaceuticals and Ascletis Pharmaceuticals have entered into a partnership to develop a systemically delivered RNAi therapeutic, ALN-VSP, for the treatment of liver cancers including hepatocellular carcinoma (HCC). Under the ...
Tags: Alnylam Pharmaceuticals, Ascletis Pharmaceuticals, HCC, ALN-VSP
TKL Research has selected Medidata CTMS clinical trial management system to expand its clinical trial operations. The software-as-a-service allows TKL to identify sites that can enroll the exact patients by measuring actual ...
Tags: clinical trial management system, pharmaceuticals industry
TG Therapeutics and Rhizen Pharmaceuticals have collaborated to develop and commercialise Rhizen PI3K delta inhibitor, TGR-1202 previously referred as RP5264. As part of the collaboration, the companies will develop TGR-1202 on a ...
Medgenics Medical Israel (MMI) has received government grant worth NIS8.1m (approximately $2.2m) from the Office of the Chief Scientist (OCS) at the Ministry of Industry, Trade and Labor of Israel. The grant will support R&D expenses for ...
Tags: government grant, Biopump platform technology, hepatitis
Galena Biopharma has reported a net loss of $6.26m, or $0.09 per share, for the third quarter ended 30 September 2012 compared to a net loss of $5.47m, or $0.09 per share, for the third quarter ended 30 September 2011. Operating loss for ...
Tags: Net Loss, operational and business development, patient enrollment